Pulse Therapeutics

About:

Pulse Therapeutics is focused on developing vascular drug delivery devices for blood clots in stroke patients.

Website: http://www.pulsetherapeutics.com

Top Investors: BioGenerator, Cultivation Capital, Missouri Technology Corporation, +ND Capital, OSF Ventures

Description:

Pulse Therapeutics is a growing medical technology company headquartered in St. Louis, Mo. The medical developer is advancing the fight against stroke, heart disease, and other conditions with its high-level treatment solutions, which utilize the latest biomedical technology and processes. Pulse’s signature offering, the MED System, was designed to harness magnet-based technology to rapidly dissolve blood clots faster than current modalities. This faster rate of delivery of FDA-approved clot-busting medication could dramatically reduce the number of lives lost each year to stroke, heart disease, and other diseases. This pioneering medical development company was founded by leading physicists Francis “Duke” Creighton and Rogers Ritter. Dr. Creighton, who also serves as Pulse’s chief technical officer, has 20-plus years of expertise in the medical technology industry, specializing in the stroke and cardiovascular sectors. He responsible for 30 patents and is a technology reviewer for the National Cancer Institute, National Science Foundation, and National Institutes of Health. The ground-breaking medical solutions of Pulse Therapeutics continues to attract investors and garner media coverage.

Total Funding Amount:

$15.7M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

St Louis, Missouri, United States

Founded Date:

2008-01-01

Contact Email:

admin(AT)pulsetherapeutics.com

Founders:

Francis Creighton, Rogers Ritter

Number of Employees:

1-10

Last Funding Date:

2016-01-27

IPO Status:

Private

Industries:

© 2025 bioDAO.ai